These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21546068)

  • 1. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies.
    Chen Y; Stirling RG; Paul E; Hore-Lacy F; Thompson BR; Douglass JA
    J Allergy Clin Immunol; 2011 Jun; 127(6):1414-7. PubMed ID: 21546068
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors.
    Gregersen S; Aaløkken TM; Mynarek G; Fevang B; Holm AM; Ueland T; Aukrust P; Kongerud J; Johansen B; Frøland SS
    Ann Allergy Asthma Immunol; 2010 Jun; 104(6):503-10. PubMed ID: 20568383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Personal experience with replacement therapy with intravenous gamma globulin].
    Litzman J; Lokaj J; Stikarovská D; Mayer J; Thon V; Eibl MM
    Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia.
    Aghamohammadi A; Allahverdi A; Abolhassani H; Moazzami K; Alizadeh H; Gharagozlou M; Kalantari N; Sajedi V; Shafiei A; Parvaneh N; Mohammadpour M; Karimi N; Sadaghiani MS; Rezaei N
    Respirology; 2010 Feb; 15(2):289-95. PubMed ID: 20051045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.
    Bonagura VR; Marchlewski R; Cox A; Rosenthal DW
    J Allergy Clin Immunol; 2008 Jul; 122(1):210-2. PubMed ID: 18602574
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases.
    Ersoy F; Tezcan I; Sanal O
    Turk J Pediatr; 1992; 34(4):203-9. PubMed ID: 1306339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
    Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
    J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.
    Lucas M; Lee M; Lortan J; Lopez-Granados E; Misbah S; Chapel H
    J Allergy Clin Immunol; 2010 Jun; 125(6):1354-1360.e4. PubMed ID: 20471071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
    Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
    Hagan JB; Fasano MB; Spector S; Wasserman RL; Melamed I; Rojavin MA; Zenker O; Orange JS
    J Clin Immunol; 2010 Sep; 30(5):734-45. PubMed ID: 20454851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of immunoglobulin prophylaxis in humoral immunodeficiency.
    Björkander J; Bake B; Hanson LA
    Monogr Allergy; 1983; 18():156-9. PubMed ID: 6646135
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunoglobulin therapy of primary humoral immunologic deficiencies].
    Bordigoni P
    Rev Prat; 2007 Oct; 57(15):1691-8. PubMed ID: 18080428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin therapy in complicated primary antibody deficiencies.
    Danieli MG; Pulvirenti F; Rocchi V; Morariu R; Quinti I
    Immunotherapy; 2016 Sep; 8(9):995-1002. PubMed ID: 27485073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
    Moore ML; Quinn JM
    Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency.
    Freiberger T; Grodecká L; Ravcuková B; Kurecová B; Postránecká V; Vlcek J; Jarkovský J; Thon V; Litzman J
    Clin Immunol; 2010 Sep; 136(3):419-25. PubMed ID: 20627700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common variable immune deficiency and treatment with intravenous immunoglobulin during pregnancy.
    Brinker KA; Silk HJ
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):464-5. PubMed ID: 22626605
    [No Abstract]   [Full Text] [Related]  

  • 19. [Common variable immunodeficiency in adults and problems of its immunotherapy].
    Borisova AM; Setdikova NKh; Kaliazina VA; Malashenkova EV; Varfolomeeva MI
    Ter Arkh; 1998; 70(5):14-20. PubMed ID: 9644735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency.
    Favre O; Leimgruber A; Nicole A; Spertini F
    Allergy; 2005 Mar; 60(3):385-90. PubMed ID: 15679727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.